Kobayashi Kazuyoshi, Sato Koji, Ando Toshihiro, Ando Kei, Imura Saori
Department of Orthopaedics Surgery, Japan Red Cross Aichi Medical Center, Nagoya Daini Hospital, Nagoya, Japan.
Department of Nursing, Japan Red Cross Aichi Medical Center, Nagoya Daini Hospital, Nagoya, Japan.
Asian Spine J. 2023 Oct;17(5):842-850. doi: 10.31616/asj.2022.0417. Epub 2023 Jul 6.
A retrospective comparative study of denosumab therapy adherence before and during the coronavirus disease 2019 (COVID-19) pandemic.
To evaluate the effect of the COVID-19 pandemic on denosumab therapy adherence in Japan.
Denosumab is a monoclonal antibody for osteoporosis treatment. Delayed denosumab injections are associated with reduced treatment responses, which was a concern during the COVID-19 pandemic.
Participants included 376 patients who received denosumab (60 mg every 6 months) from January 2013 to June 2021. The time from therapy initiation to discontinuation was used to measure persistence, and that between initial and subsequent injections was used to determine adherence. The pandemic period was from March 2020 to December 2021.
Patients were divided into those treated after March 2020 (pandemic group, n=244) and those who discontinued treatment before March 2020 (non-pandemic group, n=132). Non-persistent cases accounted for 154, including 24 (20%), 64 (19%), and 66 (53%) aged ≤59 years, 60-79 years, and ≥80 years, respectively. The overall persistence rate at 78 months was 59.2%. Postponed cases were significantly lower in the non-pandemic group than in the pandemic group (8% vs. 15%, p =0.042). Postponement with a delay of 1-2 months did not significantly differ between the two groups, but with a significant difference for a delay of ≥3 months (0% vs. 36%, p =0.024).
Denosumab adherence remained constant but postponed cases significantly increased during the COVID-19 pandemic. Better communication by health providers on denosumab adherence and alternative administration may reduce dosing interruptions in similar pandemic situations.
一项关于2019冠状病毒病（COVID-19）大流行之前及期间地诺单抗治疗依从性的回顾性比较研究。
评估COVID-19大流行对日本地诺单抗治疗依从性的影响。
地诺单抗是一种用于治疗骨质疏松症的单克隆抗体。地诺单抗注射延迟与治疗反应降低有关，这在COVID-19大流行期间是一个令人担忧的问题。
研究对象包括2013年1月至2021年6月期间接受地诺单抗治疗（每6个月60毫克）的376例患者。从治疗开始到停药的时间用于衡量持续时间，首次注射与后续注射之间的时间用于确定依从性。大流行期为2020年3月至2021年12月。
患者分为2020年3月之后接受治疗的患者（大流行组，n = 244）和2020年3月之前停止治疗的患者（非大流行组，n = 132）。非持续治疗病例有154例，其中年龄≤59岁、60 - 79岁和≥80岁的患者分别有24例（20%）、64例（19%）和66例（53%）。78个月时的总体持续率为59.2%。非大流行组的推迟治疗病例显著低于大流行组（8%对15%，p = 0.042）。两组之间延迟1 - 2个月的推迟治疗情况无显著差异，但延迟≥3个月时有显著差异（0%对36%，p = 0.024）。
在COVID-19大流行期间，地诺单抗的依从性保持不变，但推迟治疗的病例显著增加。医疗服务提供者就地诺单抗依从性和替代给药方式进行更好的沟通，可能会减少类似大流行情况下的给药中断。
